User: Guest  Login
Title:

Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6).

Document type:
Journal Article; Article
Author(s):
Wagner, U; du Bois, A; Pfisterer, J; Huober, J; Loibl, S; Luck, HJ; Sehouli, J; Gropp, M; Stahle, A; Schmalfeldt, B; Meier, W; Jackisch, C
Abstract:
BACKGROUND: Tamoxifen and gefitinib (IRESSA) combination therapy was studied in patients with ovarian cancer refractory or resistant to platinum- and taxane-based therapy. PATIENTS AND METHODS: In this phase II study, 56 patients with epithelial ovarian carcinoma or cancer of the fallopian tube or peritoneum received oral tamoxifen 40 mg/day and gefitinib 500 mg/day until progression or unacceptable toxicity. RESULTS: Seventeen patients (mean age: 59.6 years) had previously received first-line p...     »
Journal title abbreviation:
Gynecol Oncol
Year:
2007
Journal volume:
105
Journal issue:
1
Pages contribution:
132-7
Language:
eng
Fulltext / DOI:
doi:10.1016/j.ygyno.2006.10.053
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/17161453
Print-ISSN:
0090-8258
TUM Institution:
Frauenklinik und Poliklinik
 BibTeX